河北医学2017，Vol.23Issue(9)：1502-1505,4.DOI:10.3969/j.issn.1006-6233.2017.09.028
玻璃体腔注射雷珠单抗治疗老年性湿性黄斑病变疗效观察
Clinical Observation of Vitreous Cavity Injection of Ranibizumab in the Treatment of Wet Age-related Macular Degeneration
摘要
Abstract
Objective:To investigate the efficacy of vitreous cavity injection in the treatment of senile wet macular degeneration. Methods:90 elderly patients with age-related wet macular degeneration who were enrolled from May 2014 to May 2016 were randomly divided into three groups. Group A was given vitreous cav-ity injection of ranibizumab and photocoagulation. Group B patients were given only ranibizumab injection the patients were given only photocoagulation in group C, and the best corrected visual acuity, central macular thickness and the trend and complication were compared between the three groups. Results: Compared with group B and group C, the difference between 1m, 3m, 6m and 12mBCVA scores was significantly higher than that of group B and group C (P <0.01). There was a significant difference between the two groups (P <0. 01) . There was a significant difference between the two groups ( P <0.05) ; There was no significant differ-ence in the incidence of complications between the three groups ( P> 0.05) . Conclusion:Vitreous cavity in-jection of ranibizumab photocoagulation in the treatment of senile wet macular degeneration in the most signifi-cant effect, high safety, with reference.关键词
雷珠单抗/湿性黄斑病变/最佳矫正视力/中央黄斑厚度Key words
Leopard monoclonal antibody/Wet macular degeneration/Best corrected visual acui-ty/Central macular thickness引用本文复制引用
郝雪莲..玻璃体腔注射雷珠单抗治疗老年性湿性黄斑病变疗效观察[J].河北医学,2017,23(9):1502-1505,4.基金项目
青海省自然科学基金项目,(编号:2013-Z-938Q) （编号:2013-Z-938Q）
